Clinical trials of Exubera, an inhaled insulin product, found increased cases of lung cancer among those using the product. Originally projected by Pfizer to reign in multi-billion dollar profits, Pfizer vowed to stop marketing the product in October – returning the rights to Nektar Therapeutics. Exubera has not been actively marketed since the change. Nektar is no longer seeking a marketing partner for Exubera and plans to cease all spending associated with inhaled insulin programs.
The results of the trials released Wednesday found lung cancer in six of 4,740 patients who had been treated with Exubera. Only one of the 4,292 patients not treated with the drug developed lung cancer.
Read the Reuters News Story.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.